Biotech Values

[mcbio]

Iwfal: RE OGIX Phase II trial results

I assume by "events" you are referring to patient deaths. Wouldn't the company still be able to report a p-value even if there were few deaths/events? Just wondering if there's any chance that they didn't because the p-value may have been greater than .05 at this point (i.e. not stat sig).

Also, is it a valid concern to wonder if these results only pertain to a few deaths/events? If I understand what you're saying, the strong survival advantage so far may be due to just a few deaths/events so when more do occur the advantage of OGX-011 over the control arm may diminish.

Finally, do you have any thoughts on OGIX as an investment at this level ($25 million market cap)?